SART3
(Squamous Cell Carcinoma Antigen Recognized By T Cells 3 (SART3))
宿主
人
资源
合成
应用范围
Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
产品特性
This is a synthetic peptide designed for use in combination with anti-SART3 antibody (Catalog #: ARP39128_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Each Investigator should determine their own optimal working dilution for specific applications.
限制
仅限研究用
状态
Lyophilized
溶解方式
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
浓度
1 mg/mL
缓冲液
Final peptide concentration is 1 mg/mL in PBS.
注意事项
Avoid repeated freeze-thaw cycles.
储存条件
-20 °C
储存方法
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
抗原
SART3
(Squamous Cell Carcinoma Antigen Recognized By T Cells 3 (SART3))
背景
SART3 is an RNA-binding nuclear protein that is a tumor-rejection antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients and may be useful for specific immunotherapy. SART3 is found to be an important cellular factor for HIV-1 gene expression and viral replication. It also associates transiently with U6 and U4/U6 snRNPs during the recycling phase of the spliceosome cycle. This protein is thought to be involved in the regulation of mRNA splicing.
Alias Symbols: P100, p110, DSAP1, TIP110, p110(nrb), RP11-13G14
Protein Interaction Partner: AR,COIL,MEGF10,PRPF3,RNPS1,AR,C3orf17,C3orf26,CDK9,DDX47,FRG1,LSM2,LSM4,LSM6,LSM7,MEPCE,MLF1IP,NAA38,PPIH,PRPF3,PRPF31,PRPF4,RNPS1,RPF2,RRP15,SNRPB,SRBD1,TUT1,USP15,USP39,USP4